WO2009015908A3 - Anti ephb4 antibodies and antibody fragments - Google Patents
Anti ephb4 antibodies and antibody fragments Download PDFInfo
- Publication number
- WO2009015908A3 WO2009015908A3 PCT/EP2008/006451 EP2008006451W WO2009015908A3 WO 2009015908 A3 WO2009015908 A3 WO 2009015908A3 EP 2008006451 W EP2008006451 W EP 2008006451W WO 2009015908 A3 WO2009015908 A3 WO 2009015908A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody fragments
- ephb4 antibodies
- anti ephb4
- antibodies
- light
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention concerns antibodies and antibody fragments, specifically recognising the EphB4 receptor comprising heavy chains and light chain, comprising light and heavy CDR's, and their use as medicament for the treatment of pathological angiogenesis, in particular cancer therapy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08785376A EP2170955A2 (en) | 2007-07-31 | 2008-07-25 | Anti ephb4 antibodies and antibody fragments |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07075657A EP2020419A1 (en) | 2007-07-31 | 2007-07-31 | Anti ephB4 antibody fragments |
EP07075657.2 | 2007-07-31 | ||
US95377107P | 2007-08-03 | 2007-08-03 | |
US60/953,771 | 2007-08-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009015908A2 WO2009015908A2 (en) | 2009-02-05 |
WO2009015908A3 true WO2009015908A3 (en) | 2009-03-26 |
Family
ID=38739892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2008/006451 WO2009015908A2 (en) | 2007-07-31 | 2008-07-25 | Anti ephb4 antibodies and antibody fragments |
Country Status (9)
Country | Link |
---|---|
US (1) | US20090137002A1 (en) |
EP (2) | EP2020419A1 (en) |
AR (1) | AR067730A1 (en) |
CL (1) | CL2008002233A1 (en) |
PA (1) | PA8791201A1 (en) |
PE (1) | PE20090906A1 (en) |
TW (1) | TW200911836A (en) |
UY (1) | UY31258A1 (en) |
WO (1) | WO2009015908A2 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9260525B2 (en) | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
WO2009100105A2 (en) * | 2008-02-04 | 2009-08-13 | Attogen Inc. | Inhibitors of oncogenic isoforms and uses thereof |
WO2011037791A1 (en) * | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonists of pcsk9 |
JP5774595B2 (en) | 2009-10-28 | 2015-09-09 | ヤンセン バイオテツク,インコーポレーテツド | Anti-GLP-1R antibodies and their use |
CN103201287B (en) * | 2010-08-12 | 2016-04-13 | 艾托生物有限公司 | Antibody molecule of the carcinogenic isomer of fibroblast growth factor acceptor 2 and uses thereof |
CN109069627A (en) | 2016-01-14 | 2018-12-21 | 纪念斯隆-凯特琳癌症中心 | To the T cell receptor sample antibody of the derivative peptide specific of FOXP3 |
CN113398267B (en) * | 2020-03-17 | 2023-05-05 | 中国医学科学院药物研究所 | Application of EphB4 as target in screening of insulin sensitivity increasing drugs or models |
WO2023283211A2 (en) * | 2021-07-08 | 2023-01-12 | The Children's Medical Center Corporation | Cd21 antibodies and uses thereof |
CN114409792B (en) * | 2021-12-01 | 2022-08-12 | 中山大学附属第五医院 | anti-EphB 4 nano antibody |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995027061A1 (en) * | 1994-04-04 | 1995-10-12 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
WO2005090406A2 (en) * | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
WO2007130697A2 (en) * | 2006-01-05 | 2007-11-15 | Genentech, Inc. | Anti-ephb4 antibodies and methods using same |
-
2007
- 2007-07-31 EP EP07075657A patent/EP2020419A1/en not_active Withdrawn
-
2008
- 2008-07-25 EP EP08785376A patent/EP2170955A2/en not_active Withdrawn
- 2008-07-25 WO PCT/EP2008/006451 patent/WO2009015908A2/en active Application Filing
- 2008-07-30 UY UY31258A patent/UY31258A1/en not_active Application Discontinuation
- 2008-07-30 CL CL2008002233A patent/CL2008002233A1/en unknown
- 2008-07-30 PE PE2008001278A patent/PE20090906A1/en not_active Application Discontinuation
- 2008-07-30 PA PA20088791201A patent/PA8791201A1/en unknown
- 2008-07-30 US US12/182,235 patent/US20090137002A1/en not_active Abandoned
- 2008-07-30 AR ARP080103282A patent/AR067730A1/en unknown
- 2008-07-30 TW TW097128896A patent/TW200911836A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995027061A1 (en) * | 1994-04-04 | 1995-10-12 | Genentech, Inc. | Protein tyrosine kinase agonist antibodies |
WO2005090406A2 (en) * | 2004-03-12 | 2005-09-29 | Vasgene Therapeutics, Inc. | Antibodies binding to ephb4 for inhibiting angiogenesis and tumor growth |
WO2007130697A2 (en) * | 2006-01-05 | 2007-11-15 | Genentech, Inc. | Anti-ephb4 antibodies and methods using same |
Non-Patent Citations (2)
Title |
---|
DAMSCHRODER MELISSA M ET AL: "Framework shuffling of antibodies to reduce immunogenicity and manipulate functional and biophysical properties", MOLECULAR IMMUNOLOGY, vol. 44, no. 11, April 2007 (2007-04-01), pages 3049 - 3060, XP002461277, ISSN: 0161-5890 * |
SANTA CRUZ: "EphB4 (N-19): sc-7285", INTERNET CITATION, April 1999 (1999-04-01), XP002362439, Retrieved from the Internet <URL:http://www.genetimes.com.cn/support/pdf-ds/7200-7299/sc-7285.pdf> [retrieved on 20060111] * |
Also Published As
Publication number | Publication date |
---|---|
WO2009015908A2 (en) | 2009-02-05 |
UY31258A1 (en) | 2009-03-02 |
TW200911836A (en) | 2009-03-16 |
PE20090906A1 (en) | 2009-08-08 |
AR067730A1 (en) | 2009-10-21 |
CL2008002233A1 (en) | 2009-10-09 |
US20090137002A1 (en) | 2009-05-28 |
PA8791201A1 (en) | 2009-05-15 |
EP2170955A2 (en) | 2010-04-07 |
EP2020419A1 (en) | 2009-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009015908A3 (en) | Anti ephb4 antibodies and antibody fragments | |
IL184617A (en) | Anti-dr5 antibody comprising mutations in the heavy and light chain of full- length antibody 16e2 and various aspects associated therewith | |
MX2010001757A (en) | Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof. | |
WO2016077840A3 (en) | Variable new antigen receptors (vnars) directed against transferrin receptor (tfr) and their use | |
WO2009073533A3 (en) | Anti-b7h4 monoclonal antibody-drug conjugate and methods of use | |
EP3680253A3 (en) | Therapeutic dll4 binding proteins | |
EP2103628A4 (en) | Anti-claudin-3 monoclonal antibody, and treatment and diagnosis of cancer using the same | |
WO2005103081A3 (en) | Human monoclonal antibodies against cd20 | |
WO2006084075A3 (en) | Adam-9 modulators | |
WO2008066691A3 (en) | Tes7 and antibodies that bind thereto | |
WO2010059969A3 (en) | Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer | |
WO2006029219A3 (en) | Human monoclonal anti-ctla4 antibodies in cancer treatment | |
JO2913B1 (en) | Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof | |
WO2008134724A3 (en) | Methods for administering anti-il-5 antibodies | |
WO2006099698A3 (en) | Novel anti-plgf antibody | |
PL2097453T3 (en) | Monoclonal antibodies against the human anti-müllerian hormone type ii receptor (amhr-ii) | |
MX2009009926A (en) | Monoclonal human tumor-specific antibody. | |
WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
WO2006084078A3 (en) | Jam-3 and antibodies that bind thereto | |
EP1742654A4 (en) | Anti-lfl2 antibodies for the diagnosis, prognosis and treatment of cancer | |
NZ575245A (en) | Targeted binding agents directed to pdgfr-alpha and uses thereof | |
WO2009142738A3 (en) | Compositions and methods for diagnosing and treating cancer | |
MX2007004247A (en) | Angiopoietin-2 specific binding agents. | |
WO2006083852A3 (en) | Luca2 and antibodies that bind thereto | |
WO2007068750A3 (en) | Immunoglobulins directed against nogo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08785376 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2008785376 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |